IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.

Highlights ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Equities

1541

CNE100006624

Market Closed - Hong Kong S.E. Other stock markets 04:08:05 2024-05-31 EDT			5-day change	1st Jan Change
14.68 ^HKD	+1.10%		+0.55%	-50.90%

05-30	ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares	MT
05-28	ImmuneOnco Biopharmaceuticals Inc. Approves the Appointment of Guan Mei as Executive Director	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares	05-30	MT
Immuneonco Biopharmaceuticals Inc. Receives Approval from the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China for A Randomized, Double-Blind, Controlled Phase III Clinical Trial of MM01 (Timdarpacept) in Combination with Azacitidine for the First-Line Treatment of Higher-Risk Myelodysplastic Syndrome (HR MDS)	05-17	CI
ImmuneOnco Obtains Chinese Nod for Phase III Trials of Anti-Cancer Medication	04-17	MT
ImmuneOnco Biopharmaceuticals Inc. Receives Approval from the National Medical Products Administration of the People's Republic of China for the Protocol of the Phase Iii Clinical Trial of IMM01	04-17	CI
Immuneonco Biopharmaceuticals' 2023 Loss Narrows as Other Income Increases	03-26	MT
ImmuneOnco Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-25	CI
ImmuneOnco Biopharmaceuticals Inc. Announces First Patient Dosed in the Phase II Clinical Trial of IMM2510 for the Treatment of Refractory or Relapsed Alveolar Soft Part Sarcoma	11-19	CI
ImmuneOnco Biopharmaceuticals Gets US FDA's Orphan-Drug Designation for Leukemia Drug Combination	11-09	MT
ImmuneOnco Biopharmaceuticals Gets Nod to Trial Cancer Drug	11-07	MT
ImmuneOnco Biopharmaceuticals Inc. Receives an Investigational New Drug Approval from the National Medical Products Administration of the People's Republic of China	11-07	CI
ImmuneOnco Biopharmaceuticals Inc. Obtains an Investigational New Drug Approval for IMM47 for the Treatment of Solid Tumors from the National Medical Products Administration of the People's Republic of China	23-10-16	CI
Immuneonco Biopharmaceuticals Inc. Provides Updates on the Clinical Trial of Imm47	23-09-27	CI
ImmuneOnco Biopharmaceuticals Inc. Provides Updates on the Clinical Trials of IMM2510 and IMM27M	23-09-11	CI
ImmuneOnco Biopharmaceuticals Inc. has completed an IPO in the amount of HKD 318.93792 million.	23-09-04	CI
ImmuneOnco Biopharmaceuticals Raises HK$234.5 Million in Hong Kong IPO	23-09-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer